Astria Therapeutics, Inc.
0.00%
0
1454789
04635X102
Jan 25, 2026
Jan 28, 2026, 08:38 AM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Magnetar Financial LLC | Investment Adviser | 0.00% | 0 | 0 | 0 |
| Magnetar Capital Partners LP | Holding Company | 0.00% | 0 | 0 | 0 |
| Supernova Management LLC | Holding Company | 0.00% | 0 | 0 | 0 |
| David J. Snyderman | Individual | 0.00% | 0 | 0 | 0 |
Disclosure Items (5)
Class A Common Stock, par value $0.001
Astria Therapeutics, Inc.
22 BOSTON WHARF ROAD, 10TH FLOOR, BOSTON, MA, 02210
Since the filing of the Reporting Persons' Form 13D Report of the Issuer on October 24, 2025, the Reporting Persons have purchased 118,805 Shares on behalf of the Funds. The aggregate amount of funds used by the Reporting Persons in purchasing the 118,805 Shares reported herein on behalf of the Funds have come directly from the assets of the Funds, which may any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Persons was $1,501,294.83 (excluding commissions and other execution-related costs).
As of the closing of the Merger on January 23, 2026, each of the Reporting Persons may have been deemed to have beneficial ownership of 0 Shares.
As of the closing of the Merger on January 23, 2026, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 0 Shares, which represented beneficial ownership of 0% of the Shares.
Except as set forth on Schedule A attached hereto and Item 6, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule A attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on the NASDAQ and various other trading markets.
01-26-2026
99.1 Joint Filing Agreement, dated as of January 28, 2026, among the Reporting Persons. 99.2 Power of Attorney, dated as of December 22, 2022 filed by the Reporting Persons on January 28, 2026. 99.3 Schedule A, dated as of January 28, 2026.